Psyence Biomedical Ltd. has announced the launch of a pioneering psilocybin longevity research program in collaboration with researchers in South Africa. The initiative aims to investigate the potential impact of psilocybin on biological markers associated with aging, including cellular stress, inflammation, mitochondrial function, and behavioral indicators of healthspan and lifespan. The research, led by Dr. Tanya Calvey, is currently in the project commencement phase, with accelerated progress expected early next year following ethics approval. No scientific results have been presented yet; the study is in its early stages.